Publications
2025
ESMO 2025: Clinical outcomes in patients with melanoma brain metastases: 1st line treatment options
Authors: J. Mangana, N. Asher, L. Zimmer, et. al.
ESMO 2025: The role of BRAF/MEKi rechallenge in BRAFV600 mutated melanoma patients. Insights from a EUMelaReg real-world study.
Authors: I. Gavrilova, M. Weichenthal, N. Asher, et. al.
ESMO 2025: Treatment patterns using encorafenib plus binimetinib in patients with BRAF mutated melanoma
Authors: P. Mohr, M. Weichenthal, N. Asher, et. al.
ESMO 2025: Efficiency of second-line BRAF/MEK inhibitors in BRAFV600 mutated metastatic melanoma patients after first-line immunotherapy failure. A EUMelaReg real-world study.
Authors: E. Ellebaek, M. Weichenthal, I. Gavrilova, et. al.
ESMO 2025: Impact of switching from BRAF/MEK inhibition to immune checkpoint inhibition before secondary resistance in metastatic melanoma. A EUMelaReg real-world study.
Authors: M. Weichenthal, I. Gavrilova, J. Mangana, et. al.
SMR 2025: Decision Making on Adjuvant Anti-PD1 in Stage IIB/IIC Melanoma in Europe - Interim Analysis of DECIDE-II
Authors: M. Walecki, I. von Wasielewski, J. Balsalobre Yago et. al.2024
ASCO 2024: EMR Remission: Duration of Treatment after Partial or Complete Remission in Immunotherapy for Metastatic Melanoma
Authors: N. Asher, P. Mohr, E. Ellebaek et al.
Cancers 2024: Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe
Authors: M. Weichenthal, I. Gavrilova, J. Mangana et al.
ESMO 2024: COMBI-EU: Adverse Event Management of Adjuvant Dabrafenib plus Trametinib in Patients with BRAF V600-Mutation Melanoma
Authors: P. Mohr, D. Debus, I. von Wasielewski et al.
EJC Skin Cancer 2024: Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment
Authors: M. Weichenthal, I.M. Svane, J. Mangana et al.2023
ESMO 2023: Efficacy of immune checkpoint inhibition in metastatic or nonresectable melanoma after failure of adjuvant anti PD1 treatment - A EUMelaReg real world evidence study
Authors: M. Weichenthal, D. Schadendorf, L. Bastholt et al.
SMR 2023: Upfront usage of single agent anti PD1 antibodies versus combined BRAF and MEK inhibitors in metastatic or unresectable BRAF V600 mutated melanoma - A EUMelaReg real world evidence study
Authors: L. Bastholt, L. Kandolf, N. Asher et al.
EADO 2023: Modern Treatment Usage and Outcome of Patients with Advanced and High risk Non Melanoma Skin Cancer (NMSC) a Registry Based Cohort Study
Authors: M. Weichenthal, P. Ascierto, N. Asher et al.
SMR 2023: Efficacy of pembrolizumab in metastatic melanoma patients following adjuvant anti PD1 treatment
Authors: M. Weichenthal, I.M. Svane, J. Mangana et al.2022
ASCO 2022: EMRseq: Registry based outcome analysis on 1,000 patients with BRAF V600 mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF/MEK inhibition
Authors: L. Bastholt, I.M. Svane, D. Schadendorf et al.
EADO 2022: Combi-EU: BRAF-/MEK-Inhibition with Dabrafenib and Trametinib in Melanoma Patients in the Adjuvant Setting: Interim Analysis of an Observational Study on a Treatment supporting Electronic Health App.
Authors: M. Weichenthal, P. Mohr, E. Livingstone et al.